Catherine Thieblemont
Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma.
Overview
Catherine Thieblemont (Hôpital Saint-Louis, Paris) was principal investigator of EPCORE NHL-1, the pivotal trial showing the subcutaneous CD3xCD20 bispecific epcoritamab produces deep, durable responses in relapsed or refractory large B-cell lymphoma, leading to its approval. She has led LYSA trials in marginal zone and elderly DLBCL and co-chairs the EPCORE programme moving bispecifics into earlier lines.
Pages like this
not linked directly; found by shared links- PersonMichael Dickinson
Shares CD3, CD20, Bispecific antibodies, T-cell engagers (bispecific) and the tags lymphoma, bispecific.
- ProductOdronextamab
Shares EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T, CD3, CD20, T-cell engagers (bispecific).
- PersonHervé Tilly
Shares CD20, Diffuse large B-cell lymphoma and the tags lymphoma, lysa.
- PersonGilles Salles
Shares CD20, Diffuse large B-cell lymphoma and the tags lymphoma, lysa.
- ProductEpcoritamab
Shares EPCORE DLBCL-1, EPCORE NHL-1, EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T, CD3.
- ProductMosunetuzumab
Shares EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T, CD3, CD20, T-cell engagers (bispecific).
- PersonAjai Chari
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific) and the tag bispecific.
- CompanyXencor
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).